TROG Cancer Research

What TROG Cancer Research does

TROG Cancer Research (Trans-Tasman Radiation Oncology Group) is the only clinical trials group in Australia and New Zealand dedicated exclusively to radiation therapy for cancer. Founded in 1989 and headquartered at the Calvary Mater Hospital in Waratah (Newcastle), New South Wales, it is a non-profit company limited by guarantee with registered charity and DGR status. TROG coordinates multi-centre radiation oncology clinical trials across 80+ treatment centres in ANZ, with reach into 190+ facilities internationally through partnerships with EORTC, NRG Oncology, IAEA, and the Global Harmonization Group. The organisation sustains a membership of more than 1,400 radiation oncology professionals and is one of 14 federally supported Multi-Site Collaborative Cancer Clinical Trials Groups funded through Cancer Australia.

TROG's core product is the design, coordination, and quality assurance of radiation therapy clinical trials — more than 130 trials conducted to date enrolling over 15,700 participants and producing 330+ peer-reviewed publications. Underlying technical infrastructure includes a centralised Radiotherapy Quality Assurance (RTQA) Program, the TROG Imaging Databank hosted on the Elekta ProKnow platform, a CQMS credentialing system specific to RTQA, and proprietary methodological tools including SEAFARER for statistical analysis and VESPA for trial endpoint validation. The portfolio increasingly incorporates AI-enabled tooling, notably Contour ProtégéAI+ (with MIM Software) for auto-contouring and Knowledge-Based Planning via Varian RapidPlan, alongside partnerships with peer ANZ oncology trials groups (ANZUP, AGITG, COGNO, ANZGOG, ALLG) and professional bodies including RANZCR.

The business model is a hybrid non-profit funding stack. Primary income is competitive and core government grants via Cancer Australia, supplemented by NHMRC, MRFF, and provincial/state bodies. Corporate sponsorships are provided by Varian, Elekta, GenesisCare, and ICON. Earned revenue comprises membership fees ($220+GST/year full, $55+GST/year individual), fee-for-service delivery of the RTQA Program, trial management services, and a Secondary Data Analysis offering launched in April 2025 that monetises the imaging databank. Donations and philanthropic partnerships (Tour de Cure) supplement the funding base.

Name

TROG Cancer Research

Legal name

Trans Tasman Radiation Oncology Group

Website

https://trog.com.au

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

TROG Cancer Research is a non-profit clinical trials group dedicated exclusively to radiation oncology in Australia and New Zealand. Founded in 1989, it coordinates multi-centre radiotherapy trials across 80+ centres with 1,400+ members, funded through government grants, corporate sponsorships, and fee-for-service revenue.

Ownership category

akta.pro rank

Product category

Radiation Oncology Clinical Trials Research

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Radiation Oncology (HLAKAFAC)

akta.pro secondary industry

Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK)

Keywords

• Radiation oncology research
• Clinical trial management
• Radiotherapy quality assurance
• Cancer clinical trials
• Radiation medicine trials

Headquarters

HQ city

Waratah

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Government Funding: TROG Cancer Research is one of 14 Multi-Site Collaborative Cancer Clinical Trials Groups funded by the Australian Government through Cancer Australia to support Australia's capacity to develop independent, industry-led cancer clinical trials protocols.
2. Corporate Sponsorships: Partnerships with radiation oncology industry companies including GenesisCare, Varian, Elekta, and ICON Cancer Centre for sponsorship and collaboration on clinical trials.
3. Membership Fees: Full membership costs $220+GST per year with voting rights and full access. Affiliate membership is free for qualified or training professionals.
4. Donations and Fundraising: Registered charity with Deductible Gift Recipient (DGR) status enabling tax-deductible donations. Various fundraising initiatives including Trek4TROG and KM's for Cancer Research Challenge.
5. Fee-for-Service: Radiotherapy Quality Assurance, Trial Management and other fee-for-services provided to other trial groups and organisations. Fee-for-service implemented for Secondary Data Analysis from April 2025.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

TROG Cancer Research is a non-profit collaborative clinical trials group that designs, conducts, and manages multi-centre radiation therapy clinical trials across Australia and New Zealand. It provides end-to-end Clinical Trial Management Services, a Radiation Therapy Quality Assurance (RTQA) Program that credential centres and audit dosimetry, a national cancer imaging databank, secondary data analysis, and structured membership and proposal pathways for radiation oncology professionals.

Product overview

TROG Cancer Research operates as a clinical trials organization rather than a traditional product company. The organization offers a unified platform of research services focused on radiation medicine clinical trials, comprising the core Radiation Therapy Quality Assurance (RTQA) Program for protocol compliance and data quality, Clinical Trial Management Services for end-to-end trial coordination, the TROG Imaging Databank for pooled imaging data analysis, and Secondary Data Analysis capabilities. Additional offerings include the Technical Research Workshop and Annual Scientific Meeting for professional education, a Membership Program for radiation oncology professionals, and a structured New Proposal Pathway for submitting trial concepts. The organization integrates with specialized tools including MIM Software for automated contouring, Elekta ProKnow for imaging data hosting, Varian RapidPlan for knowledge-based treatment planning, and conducts Plan and Contour Challenges for quality assurance. These components work together to advance radiation therapy research across Australia and New Zealand.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Management Services Full trial coordination services from concept through conduct, completion, and publication including protocol development, ethics submissions, data management, and regulatory compliance for radiation oncology clinical trials across Australia and New Zealand.
• Radiation Therapy Quality Assurance (RTQA) Program Comprehensive quality assurance framework for clinical trials ensuring radiation therapy protocol compliance, data integrity, and participant safety across multi-centre trials, including credentialing, benchmarking, dosimetric auditing, and on-trial case reviews.
• TROG National Cancer Imaging Databank National cancer imaging databank hosted on Elekta ProKnow software, enabling pooled clinical trial data analysis for secondary research and insights across radiation therapy trials.
• Radiation Therapy Clinical Trials Portfolio of over 130 clinical trials across multiple cancer types including breast, lung, prostate, skin, head and neck, gastrointestinal, gynaecological, brain/CNS, and lymphomas, conducted across 80+ treatment centres in Australia and New Zealand and internationally.
• Secondary Data Analysis Re-examination of existing clinical trial data to answer new research questions, supported by a Data Readiness System for dataset preparation status and a Traffic Light System for visual communication, offered on a fee-for-service basis from April 2025.
• Membership Program (Full and Affiliate) Full membership at AUD $220+GST per year with voting rights, ability to become Board Member or Trial Chair, trial proposal submission, and full RTQA program access, alongside free affiliate membership for trainees and early-career professionals in radiation medicine.
• New Proposal Pathway Structured four-category system (A–D) for accepting trial proposals with a defined submission process spanning initial application, trial development, activation, accrual, and completion for radiation oncology members.
• Technical Research Workshop (TRW) Annual full-day professional workshop for radiation therapists, medical physicists, radiation oncologists, and cancer research professionals, held alongside the Annual Scientific Meeting and endorsed by ASMIRT and ACPSEM for CPD points.
• Annual Scientific Meeting (ASM) Premier annual conference bringing together over 350 researchers, health professionals, and consumers to explore the latest developments in clinical trials and radiation oncology innovation, featuring a Technical Research Workshop, Gala Dinner, and networking opportunities.
• TROG Plan and Contour Challenges Collaborative quality assurance programme conducted with Elekta ProKnow, comprising plan challenges and contouring accuracy studies across SBRT Spine, SRS Brain, SBRT Pancreas, and Head and Neck OAR assessments.
• Facility Alliance Membership Program Network of 27 Facility Alliance cancer treatment centres across Australia and New Zealand that receive collaborative group services, RTQA support, software access, training, and IT infrastructure in exchange for trial participation.

Quantifiable outcome

• Survival rates improved from less than 50% in 1980s to as high as 90% for some cancers today
• +7 more outcomes

Named customers6 records

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature6 records

Partnerships

18 partnerships are on record, tiered core and supporting.

• VariancoreTechnology or IntegrationVarian, a Siemens Healthineers company, is a corporate partner and technology sponsor of TROG Cancer Research. They provide radiation therapy technology and have collaborated on knowledge-based planning through Varian RapidPlan software integration.
• ElektacoreTechnology or IntegrationElekta is a corporate partner providing radiation oncology technology. They collaborate with TROG on the ProKnow software platform hosting the TROG National Cancer Imaging Databank and have conducted joint Plan Challenges and Contouring Accuracy Studies.
• GenesisCarecoreChannel Partner/ Reseller/ DistributorGenesisCare is a corporate partner and Gala Dinner sponsor of TROG Cancer Research. They operate radiation oncology centres and collaborate on clinical trials.
• ICON Cancer CentrecoreChannel Partner/ Reseller/ DistributorICON Cancer Centre is a corporate partner of TROG Cancer Research, providing radiation oncology services and clinical trial participation across their network.
• MIM SoftwaresupportingTechnology or IntegrationSoftware partner collaborating on automated contouring solutions and streamlined workflows for individual case review processes. Projects include Contour ProtégéAI+ and TROG 18.06 FIG Trial Workflow.
• Gamma GurussupportingTechnology or IntegrationSoftware partner providing radiation therapy expertise and technology solutions for TROG clinical trials.
• RadformationsupportingTechnology or IntegrationSoftware partner providing radiation therapy planning software solutions for TROG clinical trials.
• Calvary Mater NewcastlecoreStrategic or Co-development PartnerMajor supporter and host of TROG Cancer Research headquarters. Calvary Mater Hospital is the major cancer care centre for Hunter New England Local Health District.
• Global Harmonization Group (GHG)coreStrategic or Co-development PartnerTROG is a member of the Global Harmonization Group which aims to harmonise and improve RTQA processes and procedures across international multi-institutional cooperative clinical trials groups.
• EORTC (European Organisation for Research and Treatment of Cancer)coreStrategic or Co-development PartnerInternational collaborative partner on clinical trials including TROG 15.02 ROAM (EORTC 13.08), TROG 06.01 Low Grade Glioma (EORTC 22033-26033), and other joint trials.
• NRG OncologycoreStrategic or Co-development PartnerInternational collaborative partner including TROG 24.02 HN014 trial. Prof Quynh-Thu Le from NRG shared insights on RTQA approaches at TROG 2025 ASM.
• ANZUP (Australian and New Zealand Urogenital and Prostate Cancer Trials Group)coreStrategic or Co-development PartnerCollaborative partner on trials including TROG 15.03/ANZUP 16001 FASTRACK II kidney cancer trial.
• AGITG / GI Cancer TrialscoreStrategic or Co-development PartnerCollaborative partner on gastrointestinal cancer trials including TOPGEAR trial and RESOLUTE trial.
• COGNO (Cooperative Trials Group for Neuro-Oncology)coreStrategic or Co-development PartnerCollaborative partner on neuro-oncology trials with shared membership on board level.
• RANZCR (Royal Australian and New Zealand College of Radiologists)coreStrategic or Co-development PartnerProfessional body partner. TROG collaborates with RANZCR on SMART workshop and ACORD concept development workshops. Dr Tuan Ha serves as RANZCR FRO Director on TROG Board.
• ANZGOG (Australian New Zealand Gynaecological Oncology Group)coreStrategic or Co-development PartnerCollaborative partner on gynaecological cancer trials including ADELE trial.
• ALLG (Australasian Leukaemia and Lymphoma Group)coreStrategic or Co-development PartnerCollaborative partner on haematology trials including TROG 03.03.
• IAEA (International Atomic Energy Agency)supportingStrategic or Co-development PartnerInternational collaboration on radiation oncology trials including E33036 IAEA HCC and E33039 IAEA NPC trials.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Australasian Gastro-Intestinal Trials Group (AGITG): Cooperative cancer trials group focused on GI cancers in Australia and New Zealand. TROG and AGITG are direct peer cooperative groups sharing Cancer Australia funding and have collaborated on trials such as TOPGEAR and RESOLUTE.
• ANZUP Cancer Trials Group: Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Directly comparable to TROG as a fellow ANZ Multi-Site Collaborative Cancer Clinical Trials Group funded by Cancer Australia; TROG and ANZUP have co-led trials (e.g., FASTRACK II).
• EORTC (European Organisation for Research and Treatment of Cancer): Europe's largest cancer clinical trials cooperative group. Directly comparable to TROG as an international radiation oncology peer; TROG and EORTC co-sponsor trials (e.g., TROG 15.02 ROAM / EORTC 13.08).
• COGNO (Cooperative Trials Group for Neuro-Oncology): ANZ cancer cooperative trials group for neuro-oncology. Directly comparable to TROG as a Cancer Australia-funded Multi-Site Collaborative Cancer Clinical Trials Group with shared board-level membership and collaborative trials.
• ALLG (Australasian Leukaemia and Lymphoma Group): ANZ haematology clinical trials group. Direct peer cooperative group funded by Cancer Australia; collaborates with TROG on combined modality trials (e.g., TROG 03.03).
• NRG Oncology: US-based National Cancer Institute-funded cooperative group combining radiation, medical, and surgical oncology trials. The most direct international peer to TROG's radiation oncology focus; TROG has collaborated on TROG 24.02 HN014.
• ANZGOG (Australia New Zealand Gynaecological Oncology Group): ANZ cooperative trials group for gynaecological cancers. Peer cooperative group to TROG funded under the same Cancer Australia umbrella; collaborates with TROG on radiation-focused gynae trials such as ADELE.

Broad incumbents

• Cancer Australia: Australian Government cancer control agency and primary funder of TROG's cooperative trials group. Operates broadly in cancer research and policy rather than as a direct trial sponsor, but is the umbrella entity that anchors TROG's regulatory position.
• Royal Australian and New Zealand College of Radiologists (RANZCR): Professional body for radiologists and radiation oncologists in ANZ. Comparable as a broader healthcare/Radiation Oncology incumbent; collaborates with TROG on SMART workshops and ACORD concept development.
• International Atomic Energy Agency (IAEA): International intergovernmental organization conducting radiation oncology research programmes. Comparable to TROG as a global radiation-focused research entity; collaborates with TROG on IAEA HCC and NPC trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TROGfightcancer
• YouTubeyoutube.com/channel/UCujf2PIcRkmCo9BUPs4sMmg
• Facebookfacebook.com/TROGCancerResearch
• LinkedInlinkedin.com/company/trog-cancer-research
• Instagraminstagram.com/trogcancerresearch/?hl=en

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TROG Cancer Research